GRAIL, Inc. GRAL
99.25 USD -5.59 (-5.33%)
Regular-session close
100.25 +1.00 +1.01%
After hours · Nov 20, 5:24 PM ET
98.36 Day range 103.96
41.50 52-week range 166.48
- YTD
- +15.96%
- 1 year
- +15.88%
News
fool.com Grail vs. Tempus AI: Which Healthcare Stock Is a Better Buy for 2027? Grail is a leader in early cancer detection through its multi-cancer blood test, Galleri, which is currently undergoing large-scale clinical trials. Tempus AI operates a vast data ecosystem that…
fool.com GRAIL: 3 Key Takeaways for Long-Term Investors GRAIL completed over 174,000 Galleri tests during nine months of 2026. Third-quarter Galleri test volumes increased 24% over the prior year.benzinga.com Grail Exec Says Co. In Conversations With Commercial Payers For Galleri Cancer Test https://event.webcasts.com/starthere.jsp?ei=1780183&tp_key=ec07844a9b&tp_special=8
benzinga.com Piper Sandler Maintains Neutral on GRAIL, Raises Price Target to $130 Piper Sandler analyst David Westenberg maintains GRAIL (NASDAQ:GRAL) with a Neutral and raises the price target from $74 to $130.
benzinga.com RBC Capital Maintains Sector Perform on GRAIL, Raises Price Target to $100 RBC Capital analyst Dan Leonard maintains GRAIL (NASDAQ:GRAL) with a Sector Perform and raises the price target from $84 to $100.
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Revolution Medicines (NASDAQ:RVMD) stock rose 14.1% to $227.83 during Wednesday's after-market session. The market value of their outstanding shares is at $41.6 billion. As per the news, the…
